nature portfolio

Corresponding author(s):	ISMAIL M MERAZ
Last updated by author(s):	Apr 12, 2023

Reporting Summary

- A description of any restrictions on data availability

- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The datasets supporting the conclusions of this article are included within the article and its supplementary files.

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics							
For all statistical ar	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.						
n/a Confirmed	Confirmed						
☐ ☐ The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement						
A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly						
The statis Only comm	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.						
A descrip	tion of all covariates tested						
A descrip	tion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons						
A full desc	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)						
For null h	ypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted use as exact values whenever suitable.						
For Bayes	ian analysis, information on the choice of priors and Markov chain Monte Carlo settings						
For hierar	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes						
Estimates	\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated						
'	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.						
Software an	d code						
Policy information	about availability of computer code						
Data collection	No software or code used for data collection						
Data analysis	All the analysis performed in the study described in statistical analysis section						
	g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.						
Data							
All manuscripts m	about <u>availability of data</u> nust include a <u>data availability statement</u> . This statement should provide the following information, where applicable: s, unique identifiers, or web links for publicly available datasets						

Human	research	partici	pants
		001 0101	0000

Validation

Tarriari i escar	en participants							
Policy information abo	out studies involving human research participants and Sex and Gender in Research.							
Reporting on sex and	gender No human research participants were used in this study.							
Population characte	Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."							
Recruitment	Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.							
Ethics oversight	Identify the organization(s) that approved the study protocol.							
Note that full information	on the approval of the study protocol must also be provided in the manuscript.							
· · · · · · · · · · · · · · · · · · ·	ific reporting pelow that is the best fit for your research. If you are not sure, read the appropriate sections before making you	 ur selection.						
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences							
	locument with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf							
Life scienc	es study design							
All studies must disclo	se on these points even when the disclosure is negative.							
Sample size In	In each animal study, every experiment group had at least N=5-8 mice and in each in-vitro experiment, samples sizes were N=3 at least.							
Data exclusions No	o data were excluded							
Replication N=	=3 independent experiments were performed for each animal experiment.							
Randomization Ur	abiased, double blinded approach were followed for animal randomization in each pre-clinical studies.							
Blinding	Unbiased, double blinded approach were followed for animal randomization and selection of treatment groups in each pre-clinical studies.							
Reporting	for specific materials, systems and methods							
	rom authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whethers relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecti							
Materials & exper	rimental systems Methods							
n/a Involved in the st	· · · · · · · · · · · · · · · · · · ·							
Antibodies	ChIP-seq							
Eukaryotic cell								
	and archaeology MRI-based neuroimaging							
Animals and ot	ner organisms							
Clinical data Dual use resea	rch of concern							
MILI Dadi de lesea								
Antibodies								
Antihodies used	listed and described in materials and methods section							

All validated antibodies are used in this study, mentioned in materials and methods section

Policy information about <u>cell lines and Sex and Gender in Research</u>							
Cell line source(s)	ATCC						
Authentication	Each cell line was authenticated before study in University of Texas MD Anderson Cancer Center Core Lab						
Mycoplasma contamination	All cell lines used in this study were mycoplasma tested negative and tested intermittently by University of Texas MD Anderson Cancer Center Core Lab						
Commonly misidentified lines (See ICLAC register)	Name any commonly misidentified cell lines used in the study and provide a rationale for their use.						

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Described in materials and methods sections
No wild animals were used
Indicated the sex of the animal in methods.
This study did not involve field-collected samples
All animal experiments were carried out following approval by the MDACC institutional review board and were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the National Institutes of Health.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that	irm that:
--------------	-----------

X] The	axis	labels	state	the	marker	and	fluorochro	ome	used	(e.g.	CD4-FI	TC).
---	-------	------	--------	-------	-----	--------	-----	------------	-----	------	-------	--------	------

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

X A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Sample preparations were described in method section.
Instrument	Attune NxT Flow Cytometer, Thermo Fisher Scientific Inc
Software	Flow Jo
Cell population abundance	At least 50,000-100,000 cells were collected for FSC/SSC gate for subsequent sub-gating analysis
Gating strategy	Cells were gated first by FSC/SCC gating, then single cells gating, followed by subsequent sub-gating for the identification of positive and negative population
Tick this how to confirm the	at a figure exemplifying the gating strategy is provided in the Supplementary Information